FR19C1043I2 - Composition pharmaceutique contenant un compose actif sur le plan optique possedant une activite d'agoniste du recepteur de la thrombopoietine et son intermediaire - Google Patents

Composition pharmaceutique contenant un compose actif sur le plan optique possedant une activite d'agoniste du recepteur de la thrombopoietine et son intermediaire

Info

Publication number
FR19C1043I2
FR19C1043I2 FR19C1043C FR19C1043C FR19C1043I2 FR 19C1043 I2 FR19C1043 I2 FR 19C1043I2 FR 19C1043 C FR19C1043 C FR 19C1043C FR 19C1043 C FR19C1043 C FR 19C1043C FR 19C1043 I2 FR19C1043 I2 FR 19C1043I2
Authority
FR
France
Prior art keywords
pharmaceutical composition
composition containing
active compound
optically active
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1043C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of FR19C1043I1 publication Critical patent/FR19C1043I1/fr
Application granted granted Critical
Publication of FR19C1043I2 publication Critical patent/FR19C1043I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
FR19C1043C 2007-07-31 2019-06-28 Composition pharmaceutique contenant un compose actif sur le plan optique possedant une activite d'agoniste du recepteur de la thrombopoietine et son intermediaire Active FR19C1043I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007198590 2007-07-31
PCT/JP2008/063541 WO2009017098A1 (ja) 2007-07-31 2008-07-29 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体

Publications (2)

Publication Number Publication Date
FR19C1043I1 FR19C1043I1 (el) 2019-08-09
FR19C1043I2 true FR19C1043I2 (fr) 2020-04-03

Family

ID=40304328

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1043C Active FR19C1043I2 (fr) 2007-07-31 2019-06-28 Composition pharmaceutique contenant un compose actif sur le plan optique possedant une activite d'agoniste du recepteur de la thrombopoietine et son intermediaire

Country Status (21)

Country Link
US (2) US8530668B2 (el)
EP (1) EP2184279B1 (el)
JP (1) JP5164181B2 (el)
KR (1) KR20100027243A (el)
CN (4) CN103450110B (el)
AU (1) AU2008283357B2 (el)
BR (1) BRPI0814891A2 (el)
CA (1) CA2694567C (el)
CY (1) CY1116190T1 (el)
DK (1) DK2184279T3 (el)
ES (1) ES2528196T3 (el)
FR (1) FR19C1043I2 (el)
HR (1) HRP20150062T1 (el)
MX (1) MX2010001082A (el)
NL (1) NL300998I2 (el)
PL (1) PL2184279T3 (el)
PT (1) PT2184279E (el)
RU (1) RU2476429C2 (el)
SI (1) SI2184279T1 (el)
TW (1) TWI422371B (el)
WO (1) WO2009017098A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI564008B (zh) * 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 難溶性藥物之溶解性改善製劑
TW201406373A (zh) * 2012-06-29 2014-02-16 Shionogi & Co 含有具有血栓形成素受體促效作用之化合物之醫藥組合物
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
JP6632127B2 (ja) * 2013-12-20 2020-01-15 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
CN105412930A (zh) * 2015-08-07 2016-03-23 军事医学科学院华南干细胞与再生医学研究中心 血小板生成素受体激动剂在促进造血干细胞归巢中的用途
JP6168579B1 (ja) * 2016-02-12 2017-07-26 塩野義製薬株式会社 重度の肝機能障害のある患者のためのルストロンボパグを含有する血小板産生促進剤
CN106083759B (zh) * 2016-06-15 2022-02-15 上海丸全化学科技有限公司 一种芦曲泊帕的全新合成工艺
EP3511332A4 (en) * 2016-09-08 2020-03-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NOVEL 2-ACYLAMINOTHIAZOLE DERIVATIVE, PREPARATION PROCESS AND USE THEREOF
CN106565625B (zh) * 2016-11-04 2018-01-30 杭州励德生物科技有限公司 一种抗血小板减少症新药Lusutrombopag中间体的制备方法
CN109311831B (zh) * 2017-02-14 2021-07-09 四川科伦药物研究院有限公司 4-苯基噻唑衍生物的晶型及其制备方法
CN109970678B (zh) * 2017-12-28 2024-03-08 四川科伦药物研究院有限公司 4-苯基噻唑衍生物无定形及其制备方法和用途
EP3808736B1 (en) * 2018-06-08 2023-08-09 Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Crystal form of 4-phenylthiazole derivative and preparation method thereof
CN113164455A (zh) * 2018-12-04 2021-07-23 盐野义制药株式会社 难溶性药物的固体分散体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001220B1 (ru) 1995-06-07 2000-12-25 Глаксо Груп Лимитед Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
JPH1072492A (ja) 1996-09-02 1998-03-17 Hokuriku Seiyaku Co Ltd ペプチド化合物
JPH10287634A (ja) 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
JPH111477A (ja) 1997-06-12 1999-01-06 Hokuriku Seiyaku Co Ltd １，４−ベンゾジアゼピン誘導体及びその用途
JPH11152276A (ja) 1997-11-20 1999-06-08 Hokuriku Seiyaku Co Ltd ベンゾジアゼピン誘導体
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
KR20020069183A (ko) 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
US20040063764A1 (en) * 2001-01-26 2004-04-01 Hiroshi Takemoto Halogen compounds having thrombopoietin receptor agonism
WO2002062775A1 (fr) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
SI1466912T1 (sl) 2002-01-18 2013-08-30 Astellas Pharma Inc. Derivat 2-acilaminotiazola ali njegova sol
JP4317818B2 (ja) 2002-09-30 2009-08-19 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体の新規な塩
US6737382B1 (en) * 2002-10-23 2004-05-18 Nippon Soda Co. Ltd. Insecticidal aminothiazole derivatives
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
CA2529686C (en) 2003-07-17 2010-06-15 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
CN1863783A (zh) * 2003-08-12 2006-11-15 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
MXPA06002567A (es) * 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
JP4665769B2 (ja) 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
WO2007004038A1 (en) 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
US8515798B2 (en) 2005-09-27 2013-08-20 Accenture Global Services Gmbh Closed-loop supply chain in the paper packaging sector
AU2006313491B2 (en) 2005-11-08 2011-01-06 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia

Also Published As

Publication number Publication date
US8889722B2 (en) 2014-11-18
EP2184279B1 (en) 2014-11-12
AU2008283357B2 (en) 2011-08-11
HRP20150062T1 (hr) 2015-04-10
CN101809008A (zh) 2010-08-18
CN103393678A (zh) 2013-11-20
CA2694567C (en) 2013-04-23
AU2008283357A1 (en) 2009-02-05
DK2184279T3 (en) 2015-01-26
US20100267783A1 (en) 2010-10-21
EP2184279A1 (en) 2010-05-12
PL2184279T3 (pl) 2015-04-30
NL300998I1 (nl) 2019-07-03
SI2184279T1 (sl) 2015-04-30
RU2476429C2 (ru) 2013-02-27
PT2184279E (pt) 2015-02-05
TW200914000A (en) 2009-04-01
CN103396313B (zh) 2015-05-13
CY1116190T1 (el) 2017-02-08
CN103396313A (zh) 2013-11-20
TWI422371B (zh) 2014-01-11
US8530668B2 (en) 2013-09-10
ES2528196T3 (es) 2015-02-05
NL300998I2 (nl) 2019-08-28
CN103450110B (zh) 2015-12-09
MX2010001082A (es) 2010-03-01
CA2694567A1 (en) 2009-02-05
FR19C1043I1 (el) 2019-08-09
KR20100027243A (ko) 2010-03-10
BRPI0814891A2 (pt) 2015-08-18
JP5164181B2 (ja) 2013-03-13
RU2010107169A (ru) 2011-09-10
WO2009017098A1 (ja) 2009-02-05
EP2184279A4 (en) 2011-11-02
CN101809008B (zh) 2013-09-18
JPWO2009017098A1 (ja) 2010-10-21
CN103450110A (zh) 2013-12-18
US20130217885A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
FR19C1043I2 (fr) Composition pharmaceutique contenant un compose actif sur le plan optique possedant une activite d'agoniste du recepteur de la thrombopoietine et son intermediaire
MA28937B1 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
MA29034B1 (fr) Posologie d'un agoniste du recepteur s1p
ITMI20052461A1 (it) Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
FR2898356B1 (fr) Diesters d'acides carboxylique ramifies
BRPI0915411A2 (pt) partículas revestidas contendo agentes farmaceuticamente ativos
MA28851B1 (fr) Procédé d'assemblage de dispositifs de délivrance de médicaments
BRPI0818339A2 (pt) Produto de dispersão sólida contendo composto à base de n-aril uréia
FR2938767B1 (fr) Composition photoprotectrice contenant un amidon gelifiant et des particules de polyamide
BRPI0813926A2 (pt) Utilização de uma substância, composição e métodos de triagem de princípios ativos que inibem a formação dos ages e de cuidado cosmético.
FR2903405B1 (fr) Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
DE602005009812D1 (de) Abgabesystem für wirkstoff
GT200500051A (es) Nuevos derivados de bencil (ideno)-lactamas
FR2881508B1 (fr) Distributeur d'agent lubrifiant
DE602005004039D1 (de) Nicht-peptidische bradykinin-antagonisten und pharmazeutische zusammensetzungen daraus
BRPI0908675A2 (pt) "composto, composição farmacêutica, método de tratamento de um distúrbio relacionado à angiogênese e método de inibição da atividade do receptor do fator de crescimento epidérmico"
BRPI0818988A2 (pt) "chip de alimentação líquida e métodos de análise e de alimentação de líquidos"
FR2925326B1 (fr) Utilisation d'un hydrolysat de mais en tant que principe actif activateur de la synthese des aquaporines
BRPI0815668A2 (pt) compostos pirrol tendo atividade biológica antagonista e agonista de receptor de esfingosina-1-fosfato.
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs
FR2896151B1 (fr) Composition d'emulsion de type huile-dans-eau encapsulee
FR2931677B1 (fr) Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
ITMI20041255A1 (it) Sistemi microparticellari per somministrazione orale di sostanze biologicamente attive
ATE552005T1 (de) Pharmazeutische zusammensetzung hyaluronan als aktive komponente enthaltend